公开(公告)号：US10954233B2

公开(公告)日：2021-03-23

申请号：US16330820

申请日：2017-09-06

Applicant: Novartis AG

Inventor： Phillip Alper ,  Jonathan Deane ,  Songchun Jiang ,  Tao Jiang ,  Thomas Knoepfel ,  Pierre-Yves Michellys ,  Daniel Mutnick ,  Wei Pei ,  Peter Syka ,  Guobao Zhang ,  Yi Zhang

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  A61P17/06 ,  A61P1/16 ,  A61P37/06 ,  A61P19/02 ,  A61K31/496 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06

Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.

公开(公告)号：US20220071971A1

公开(公告)日：2022-03-10

申请号：US17415335

申请日：2019-12-18

Applicant: NOVARTIS AG

Inventor： Mihai Azimioara ,  Badry Bursulaya ,  Songchun Jiang ,  Casey Jacob Nelson MATHISON ,  Victor Ivanovich NIKULIN ,  Truc Ngoc NGUYEN ,  Barun OKRAM ,  Sejal PATEL ,  Dean Paul PHILLIPS ,  Lewis WHITEHEAD ,  Baogen WU ,  Shanshan YAN ,  Xuefeng ZHU

IPC: A61K31/439 ,  A61K45/06 ,  C07D515/18 ,  C07D513/22 ,  C07D513/18 ,  A61K31/5377

Abstract: The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.